A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age.
Atogepant is a medicine currently approved in the United States and Europe for the preventive treatment of migraine in adult patients with migraine and is being studied for the preventative treatment of chronic migraine in participants between the ages of 12 and 17 years. Participants will be randomly assigned to one of the 2 groups to be treated with either atogepant or placebo. This study is double-blinded, which means that neither the patients nor the study doctors know who is given which study treatment. Approximately 420 participants 12 to 17 years of age with chronic migraine will be enrolled at approximately 70 sites across the world.
Participants will receive oral tablets of atogepant or placebo once daily for 12 weeks and will be followed for 4 weeks.
Participants will attend regular visits during the study at a hospital or clinic and the effects of treatment will be checked by completion of a daily diary, medical assessments, blood tests, checking for side effects, and completing questionnaires.
Inclusion Criteria:
History of chronic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) (2018) for at least 6 months as of Visit 1.
During the last 28 days of the screening/baseline period, and as per eDiary:
Exclusion Criteria:
abbvieclinicaltrials@abbvie.com844-663-3742
Huntsville, Alabama 35805, United States
Fayetteville, Arkansas 72703, United States
Gulf Breeze, Florida 32561, United States
Winter Park, Florida 32789, United States
Ann Arbor, Michigan 48104, United States
Papillion, Nebraska 68046, United States
Nashua, New Hampshire 03060, United States
Scottdale, Pennsylvania 15683, United States
Smithfield, Pennsylvania 15478, United States
Austin, Texas 78723-3079, United States
Kingwood, West Virginia 26537, United States
London, Ontario N6A 5W9, Canada
Shibuya-ku, Tokyo 151-0051, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Tendo-shi, Yamagata 994-0083, Japan
Poznan, Greater Poland Voivodeship 60-848, Poland
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-752, Poland
Krakow, Lesser Poland Voivodeship 30-539, Poland
Wroclaw, Lower Silesian Voivodeship 52-210, Poland
Almada, Setúbal District 2805-267, Portugal
London, Greater London WC1N 3HZ, United Kingdom
＋81-6-6643-2660
351 21 294 0294